BTAI

BioXcel Therapeutics, Inc. (BTAI) | Rumor.io

BioXcel Therapeutics

BTAI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,277

Bullish sentiment (50-day avg)26%

Price to earnings ratio-0.01

Market capitalization1.3M

Earnings per share-2.58

Dividend yield (TTM)—

Revenue (annual)642K

Net income (annual)-69.9M

Social

What share of all stock conversation is about BTAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Sep 4

BioXcel Therapeutics, Inc. ($BTAI) is shifting to OTC, effective September 8, with a new ticker of BTAIQ.
The company's CEO, Vimal Mehta, has been criticized for his management of resources, with some accusing him of mismanaging the company to the point of potential bankruptcy.
$BTAI has been experiencing significant price drops, with a 31.3% drop after hours and a new low of $0.07, accompanied by high trading volumes.

Generated by AI

Sentiment

Of the messages about BTAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	22.54% -5.49	73.36% -1.71
Bearish	—	—	77.46% +5.49	26.64% +1.71

Bullish· Mar 9

$BTAI is expected to surprise on the upside, with some news potentially coming sooner than anticipated, contributing to a 5% price increase in a weak market.
The stock has a high short interest of 1,937,441 shares, with shorts paying a 13.9% borrow fee, making it increasingly expensive to hold short positions.
Accumulating buying pressure and a sharp rise may be just around the corner, with momentum gathering behind the scenes, making it a potential candidate for an upside surge.

Bearish· Sep 4

The CEO's inability to manage resources may have led to the company's struggles, with the stock potentially being approved by the FDA in November.
The company's debt and financial situation are precarious, with some suggesting it may be a "shell with massive debt" that is "worthless."
The stock's recent performance has been negative, with one post suggesting it may be a "dead money" investment, and another predicting it will continue to decline, potentially reaching as low as 2 cents.

Generated by AI

Topics

Of the messages about BTAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	5.72%	36.69%
Technical Analysis	—	—	24.85%	34.23%
Macro	—	—	44.38%	16.39%
Analysts	—	—	24.85%	10.66%
Controversies	—	—	0.2%	0.94%
Earnings	—	—	0%	1.09%

Earnings· Aug 12

BioXcel Therapeutics, Inc. reported a Q-2 loss and a 32% miss on EPS, with sales of $120.00K missing the $283.33K estimate.
The earnings report was expected to be bad, and investors bought the stock for catalysts such as upcoming topline phase 3 results.
The upcoming topline phase 3 results are expected to be a major catalyst for the stock, potentially giving BioXcel Therapeutics a total monopoly in an 8B at-home treatment market.

Analysts· Jun 30

Analysts are very confident about BioXcel Therapeutics ($BTAI), with a buy consensus of 83% based on analysis from 16 analysts.
Mizuho Securities maintains a Buy rating and a $40 price target for BioXcel Therapeutics ($BTAI), while Bank of America has lowered its price target to $23.
The average 12-month price target for BioXcel Therapeutics ($BTAI) is $49.86, with a high of $66.00 and a low of $25.00, according to 7 analyst price targets.

Announcements· Aug 28

BioXcel Therapeutics, Inc. (BTAI) has filed for Chapter 11 bankruptcy and entered into an asset sale agreement with Teva Pharmaceuticals, which will serve as the sole "stalking horse bidder" for the sale of substantially all of BTAI's assets.
The asset sale agreement includes an upfront payment of $57.5 million, with potential milestone payments totaling up to $67.5 million, and Teva will assume certain liabilities.
BTAI's stock has been delisted from Nasdaq and will begin trading on the OTC Markets, and the company's equity is likely to be wiped out due to the bankruptcy filing and asset sale agreement.

Technical Analysis· Mar 5

$BTAI is trading below key resistance levels of $2.19 and $2.50, with a falling pennant pattern forming, suggesting a potential short opportunity.
The stock has been showing signs of coiling and pennant formation, with a possible break out at the open, but volume is drying up, making it challenging to break through the $2 barrier.
The technical analysis suggests that $BTAI is in a downtrend, with a possible short opportunity below $1.90, and a stop-loss at $2.25, with a potential target of $1.92.

Generated by AI

Community

Of the messages about BTAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	17.21%	54.96%
Newcomers	0%	0%	82.79%	45.04%

Regulars· Sep 4

The regulars are criticizing BioXcel Therapeutics' CEO, Vimal Mehta, for his handling of the company, specifically the failure to obtain FDA approval for a treatment in November.
The company's management and potential for selling the company are being questioned by the regulars, with some suggesting that the thought of selling the company may not have occurred to the CEO.
The regulars are warning others not to fall into a "pump and dump" trap, as they believe BioXcel Therapeutics is a worthless shell with massive debt, and that it is likely to end up in chapter 11 with Teva getting the assets.

Newcomers· Sep 4

Newcomers are focused on the sharp decline in price, with one post mentioning a 31.3% drop after hours and another a 23.4% drop in the pre-market.
Some newcomers are using historical data to try to predict the stock's movement, citing a 20% chance of a bounce after a 30% gap down.
The company's debt and revenue are a concern, with one post stating that the company has $400 million in debt and another mentioning the sale of BXCL501 for $125 million, leading one user to call it "dead money".

Generated by AI

News

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

17d agoYahoo Finance

Biotech filed for bankruptcy 11 weeks before its big FDA decision

22d agothestreet.com

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

25d agoYahoo Finance

Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August

25d agobenzinga.com

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

1mo agoYahoo Finance

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.

1mo agoYahoo Finance

Also Discussed

Investors talking about BTAI also mention

#	Name	Attention
1	Incannex Healthcare Inc.IXHL	0.01%0
2	Tharimmune Inc.THAR	0%new
3	BSLK - Bolt Projects Holdings, Inc.	——
4	Shattuck Labs, Inc.STTK	0%new
5	Axsome Therapeutics IncAXSM	0.01%0
6	MODV - ModivCare Inc.	——
7	IO Biotech, Inc.IOBT	0%0
8	X4 Pharmaceuticals, Inc.XFOR	0%0
9	CaliberCos Inc. Class A Common StockCWD	0%0
10	AtlasClear Holdings, Inc.ATCH	0.01%0

BioXcel Therapeutics, Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology using artificial intelligence and data-driven drug discovery. Its current portfolio includes IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, as well as investigational programs built around BXCL501 and other proprietary candidates. The company’s neuroscience work addresses conditions such as agitation in dementia and major depressive disorder, while its immuno-oncology efforts are centered on oral immune-activating therapies for aggressive cancers through its subsidiary, OnkosXcel Therapeutics. Headquartered in New Haven, Connecticut, BioXcel Therapeutics operates as a commercial-stage specialty biotechnology company with a focus on advancing targeted treatment options in areas with significant unmet medical need.

Website

Location

555 Long Wharf Drive

New Haven, CT, 06511

United States

Social

What share of all stock conversation is about BTAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% -0.02

Sep 4

BioXcel Therapeutics, Inc. ($BTAI) is shifting to OTC, effective September 8, with a new ticker of BTAIQ.
The company's CEO, Vimal Mehta, has been criticized for his management of resources, with some accusing him of mismanaging the company to the point of potential bankruptcy.
$BTAI has been experiencing significant price drops, with a 31.3% drop after hours and a new low of $0.07, accompanied by high trading volumes.

Generated by AI

Sentiment

Of the messages about BTAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	22.54% -5.49	73.36% -1.71
Bearish	—	—	77.46% +5.49	26.64% +1.71

Bullish· Mar 9

$BTAI is expected to surprise on the upside, with some news potentially coming sooner than anticipated, contributing to a 5% price increase in a weak market.
The stock has a high short interest of 1,937,441 shares, with shorts paying a 13.9% borrow fee, making it increasingly expensive to hold short positions.
Accumulating buying pressure and a sharp rise may be just around the corner, with momentum gathering behind the scenes, making it a potential candidate for an upside surge.

Bearish· Sep 4

The CEO's inability to manage resources may have led to the company's struggles, with the stock potentially being approved by the FDA in November.
The company's debt and financial situation are precarious, with some suggesting it may be a "shell with massive debt" that is "worthless."
The stock's recent performance has been negative, with one post suggesting it may be a "dead money" investment, and another predicting it will continue to decline, potentially reaching as low as 2 cents.

Generated by AI

Topics

Of the messages about BTAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	5.72%	36.69%
Technical Analysis	—	—	24.85%	34.23%
Macro	—	—	44.38%	16.39%
Analysts	—	—	24.85%	10.66%
Controversies	—	—	0.2%	0.94%
Earnings	—	—	0%	1.09%

Earnings· Aug 12

BioXcel Therapeutics, Inc. reported a Q-2 loss and a 32% miss on EPS, with sales of $120.00K missing the $283.33K estimate.
The earnings report was expected to be bad, and investors bought the stock for catalysts such as upcoming topline phase 3 results.
The upcoming topline phase 3 results are expected to be a major catalyst for the stock, potentially giving BioXcel Therapeutics a total monopoly in an 8B at-home treatment market.

Analysts· Jun 30

Analysts are very confident about BioXcel Therapeutics ($BTAI), with a buy consensus of 83% based on analysis from 16 analysts.
Mizuho Securities maintains a Buy rating and a $40 price target for BioXcel Therapeutics ($BTAI), while Bank of America has lowered its price target to $23.
The average 12-month price target for BioXcel Therapeutics ($BTAI) is $49.86, with a high of $66.00 and a low of $25.00, according to 7 analyst price targets.

Announcements· Aug 28

BioXcel Therapeutics, Inc. (BTAI) has filed for Chapter 11 bankruptcy and entered into an asset sale agreement with Teva Pharmaceuticals, which will serve as the sole "stalking horse bidder" for the sale of substantially all of BTAI's assets.
The asset sale agreement includes an upfront payment of $57.5 million, with potential milestone payments totaling up to $67.5 million, and Teva will assume certain liabilities.
BTAI's stock has been delisted from Nasdaq and will begin trading on the OTC Markets, and the company's equity is likely to be wiped out due to the bankruptcy filing and asset sale agreement.

Technical Analysis· Mar 5

$BTAI is trading below key resistance levels of $2.19 and $2.50, with a falling pennant pattern forming, suggesting a potential short opportunity.
The stock has been showing signs of coiling and pennant formation, with a possible break out at the open, but volume is drying up, making it challenging to break through the $2 barrier.
The technical analysis suggests that $BTAI is in a downtrend, with a possible short opportunity below $1.90, and a stop-loss at $2.25, with a potential target of $1.92.

Generated by AI

Community

Of the messages about BTAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	17.21%	54.96%
Newcomers	0%	0%	82.79%	45.04%

Regulars· Sep 4

The regulars are criticizing BioXcel Therapeutics' CEO, Vimal Mehta, for his handling of the company, specifically the failure to obtain FDA approval for a treatment in November.
The company's management and potential for selling the company are being questioned by the regulars, with some suggesting that the thought of selling the company may not have occurred to the CEO.
The regulars are warning others not to fall into a "pump and dump" trap, as they believe BioXcel Therapeutics is a worthless shell with massive debt, and that it is likely to end up in chapter 11 with Teva getting the assets.

Newcomers· Sep 4

Newcomers are focused on the sharp decline in price, with one post mentioning a 31.3% drop after hours and another a 23.4% drop in the pre-market.
Some newcomers are using historical data to try to predict the stock's movement, citing a 20% chance of a bounce after a 30% gap down.
The company's debt and revenue are a concern, with one post stating that the company has $400 million in debt and another mentioning the sale of BXCL501 for $125 million, leading one user to call it "dead money".

Generated by AI

BioXcel Therapeutics

Social

Sep 4

Bullish· Mar 9

Bearish· Sep 4

Earnings· Aug 12

Analysts· Jun 30

Announcements· Aug 28

Technical Analysis· Mar 5

Regulars· Sep 4

Newcomers· Sep 4

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Biotech filed for bankruptcy 11 weeks before its big FDA decision

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

Also Discussed

BioXcel Therapeutics, Inc.

Company Information

Location

Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain

Biotech filed for bankruptcy 11 weeks before its big FDA decision

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August

Teva Pharmaceuticals to acquire BioXcel assets for up to $125m

Teva Seeks to Boost Neuroscience Portfolio With BioXcel Asset Bid

Also Discussed

Social

Sep 4

Bullish· Mar 9

Bearish· Sep 4

Earnings· Aug 12

Analysts· Jun 30

Announcements· Aug 28

Technical Analysis· Mar 5

Regulars· Sep 4

Newcomers· Sep 4